Table 2.
Features of (neo)adjuvant chemotherapy and other treatments
| PBC/LRs in BRCA1/2 mutation carriers (n = 86) | PBC/LRs in sporadic patients (n = 618) | p value | |
|---|---|---|---|
| Planned chemotherapy regimen, n (%) | |||
| Containing both anthracyclines and taxanes | 49 (57) | 443 (72) | <0.001 |
| 3 × FE100C/3 × D | 46 (53) | 290 (47) | |
| 4 × AC/12 × P | 1 (1) | 103 (17) | |
| 6 × TAC | 1 (1) | 40 (6) | |
| Other | 1 (1) | 10 (2) | |
| Containing anthracyclines and no taxanes | 30 (35) | 163 (26) | |
| 5 × FE90C | 19 (22) | 86 (14) | |
| 6 × FE90C | 7 (8) | 60 (10) | |
| 4 × AC | 1 (1) | 13 (2) | |
| Other | 3 (3) | 4 (1) | |
| Containing taxanes and no anthracyclines | 7 (8) | 12 (2) | |
| Dose-dense regimens, n (%) | 3 (3) | 1 (0.2) | <0.001 |
| Regimens with standard G-CSF prophylaxis, n (%) | 4 (5) | 41 (7) | 0.48 |
| Regimens with weekly chemotherapy, n (%) | 1 (1) | 104 (17) | <0.001 |
| Number of 3-weekly chemotherapy cycles, median (range) | 6 (3–10) | 6 (1–8) | 0.14 |
| Previous chemotherapy, n (%) | 11 (13) | 31 (5) | <0.01 |
| Adjuvant radiotherapy before chemotherapy, n (%) | 2 (2) | 87 (14) | <0.01 |
| Neoadjuvant chemotherapy, n (%) | 10 (12) | 81 (13) | 0.70 |
PBC/LR primary breast cancer or local/locoregional recurrence, 3 × FE100C/3 × D three cycles of 3-weekly fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2, followed by three cycles of docetaxel 100 mg/m2, 4 × AC/12 × P four cycles of 3-weekly doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, followed by 12 cycles of weekly paclitaxel 80 mg/m2, 6 × TAC six cycles of 3 weekly docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2, 5 × FE90C five cycles of 3-weekly fluorouracil 500 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 500 mg/m2, 6 × FE90C six cycles of 3-weekly fluorouracil 500 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 500 mg/m2, 4 × AC four cycles of 3-weekly doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, G-CSF granulocyte colony-stimulating factor